NCT05599932View on ClinicalTrials.gov

Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 2, 2022

Primary Completion Date

September 18, 2023

Study Completion Date

September 18, 2023

Conditions
Hepatic Impairment
Interventions
DRUG

Siremadlin

HDM201 capsule

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

78215

Texas Liver Institute, San Antonio

33014-3616

Clinical Pharmacology of Miami LLC, Miami

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY